You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. AAV2-ASPA-Based Metabolic Intervention for Alzheimer's Disease

    SBC: ASKLEPIOS BIOPHARMACEUTICAL, INC.            Topic: NIA

    Abstract We propose to initiate preclinical development of a gene therapeutic targeted to Alzheimer's Disease. The World Health Organization's and Alzheimer's Disease International's report on Dementia (2012) recognizes that the global burden of AlzheimerDisease is forecast to worsen significantly with prevalence predicted to double every 20 years. Interventions that could prov ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. A cell-free, high-throughput screening service for accelerated GPCR ligand discovery

    SBC: KXT BIO INC.            Topic: 300

    PROJECT SUMMARY The proposed Phase I STTR project is a partnership between a biotechnology company KXTbioIncand the University of North Carolina at Chapel Hill to develop an innovative high throughput screening service for identifying new drug candidates that act via G protein coupled receptorsGPCRsThis large protein superfamily has been the most successful source of therapeutic targetsaccounting ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  3. A momentum-enabled treadling methodology to improve gait and enhance mobility in patients with peripheral arterial disease

    SBC: TREADWELL CORPORATION            Topic: NIA

    Project SummaryA significant cause of mobility impairment in the elderly is peripheral arterial diseasePADPAD results in significant functional declinereduced walking speed and distanceand lower physical activity levelsresulting in a loss of independence and impaired quality of lifeThe most effective therapy for PAD is rigorous exercisee gwalkingHowevermost PAD patients will not participate in sup ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  4. An integrated neural network analysis and video microscopy platform for fully automated particle tracking

    SBC: AI Tracking Solutions LLC            Topic: 400

    Project Summary AbstractParticle trackingPTis a biophysical tool for elucidating molecular interactionstransport phenomena of diverse speciesand rheological properties of complex materialsPT experiments involve first obtaining high resolution videos that capture time resolved increments of particlesfollowed by extraction of traces of entities of interest from videos in the form of spatial location ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  5. A novel therapeutic approach for Acute Lung Injury/ARDS

    SBC: BIOMARCK PHARMACEUTICALS, LTD            Topic: NHLBI

    DESCRIPTION (provided by applicant): The objective of the proposed project is to advance the development of novel peptides targeting MARCKS (Myristoylated Alanine-Rich C Kinase Substrate) protein as platform drug molecules for the treatment of Acute Lung Injury (ALI) and its more severe form, Acute Respiratory Distress Syndrome (ARDS), thereby providing the first pharmacologic therapeutic for this ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Chemical Libraries Targeting Epigenetic Methyl Writers and Erasers

    SBC: Epicypher, Inc.            Topic: 102

    PROJECT SUMMARYIn this proposalEpiCypher is partnering with DrJian Jina leader in medicinal chemistry and epigenetic drug discoveryto develop the first epigenetics focused chemical library for histone methylationSmall molecule inhibitors that target histone methylation are an emerging class of therapeutics for cancer treatmentThis hot bed of drug development is fueled by the identification of nume ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  7. CN-105 Improves Functional Outcome After Intracranial Hemorrhage

    SBC: AegisCN LLC            Topic: 106

    ABSTRACT Intracerebral hemorrhageICHis a devastating form of cerebrovascular disease with no FDAapproved treatmentsIt is generally accepted that ICH induced neuroinflammatory responses mediate development of cerebral edemaintracranial hypertensionand secondary neuronal injuryOne promising strategy for ICH neuroinflammatory modulation is through the downstream effects of apolipoprotein EapoEPreviou ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Development of a Designer Proline-rich antimicrobial peptide Chaperone protein inhibitor (DPC) for treating multi-drug resistant bacteremia

    SBC: Arrevus, Inc.            Topic: NIAID

    Bloodstream infectionsBSIscaused by Gram negative bacterial pathogens are associated with significant morbidity and mortality due to the antibiotic resistant nature of the pathogensInfections caused by multi drug resistantMDRbacterial pathogens result in substantial health and economic impact due to the lack of effective therapeutic optionsThis lack of treatment options is particularly relevant fo ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  9. Development of a Designer Proline-rich antimicrobial peptide Chaperone protein inhibitor (DPC) for treating multi-drug resistant urinary tract infections

    SBC: Arrevus, Inc.            Topic: NIAID

    Urinary tract infectionsUTIsare one of the most common hospital acquired infections and are often caused by multi drug resistantMDRbacterial pathogensMDR bacterial pathogens are associated with significant morbidity and mortalitycreating enormous healthcare and economic burdens due to variations in disease natural histories as well as the lack of effective therapeutic optionsTreatment option limit ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  10. Development of a Designer Proline-rich antimicrobial peptide Chaperone protein inhibitor (DPC) for treating multi-drug resistant wound infections

    SBC: Arrevus, Inc.            Topic: NIAID

    Project SummaryOver $billion is spent annually in the US treating chronicnon healing woundsmany of which face lifethreatening complications due to infectionsWound infections are difficult to treat due to the frequency of antibiotic resistance as well as the formation of biofilmsa community of bacteria covered by an extracellular polymeric substanceBiofilm related infections can result in a substan ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government